FOR IMMEDIATE RELEASE

BioFire FilmArray® Respiratory Panel Decreases Turnaround Time and Improves Patient Care

Study Published in January 2013 issue of American Journal of Clinical Pathology

SALT LAKE CITY, Utah (February 12, 2013) - BioFire Diagnostics, Inc. today announced new data from Seattle Children’s Hospital in Seattle, Washington demonstrating how the FilmArray Respiratory Panel (RP) improves detection and reporting turnaround time for respiratory viruses. Investigators at Seattle Children’s were able to achieve a greater than fourfold reduction in average and median turnaround time using FilmArray RP compared to standard processes. Additionally, 81 percent of patients testing positive for Influenza A or Influenza B received a prescription of Tamiflu® (oseltamivir) within three hours of discharge. Current guidelines call for the medication to be given within 48 hours of symptom onset in order to be most effective.

Investigator Min Xu, MD, PhD, Seattle Children’s commented, “The implementation of FilmArray RP in our core laboratory significantly decreased the time required to detect and report respiratory viruses. Patients with influenza were treated rapidly and appropriately, which had previously not been possible.” She also noted, “Detection of other viral agents assisted physicians in the differential diagnosis of respiratory syndromes and isolation of patients admitted to the hospital. Overall, we implemented a molecular-based efficient diagnostic testing process in our core laboratory for the first time. Our results demonstrate that molecular technology can be successfully deployed in a non-specialty, multidisciplinary core laboratory.”

The study, titled “Implementation of FilmArray Respiratory Viral Panel in a Core Laboratory Improves Testing Turnaround Time and Patient Care,” included 2,537 specimens from pediatric patients prospectively collected and tested between December 2011 and April 2012. The average and median turnaround times were 1.6 and 1.4 hours, respectively, in contrast to 7.0 and 6.5 hours documented one year previously at an on-site reference laboratory using direct fluorescence assay (DFA). During the study period, rhinovirus was detected in 20 percent and coronavirus in 6 percent of samples using the FilmArray RP. These viruses would not have been detected with DFA.

For further information, please visit www.BioFireDx.com.

About BioFire Diagnostics, Inc.
BioFire Diagnostics, Inc., formerly Idaho Technology, Inc., is a privately held clinical diagnostics company based in Salt Lake City, Utah. The Company manufactures and distributes the FilmArray RP, which operates on the user-friendly, patented FilmArray system, to hospital-based clinical laboratories across the U.S. and EU. With the FilmArray RP, BioFire provides the only FDA-cleared clinical diagnostic test for eight of the 20 organisms in its panel. In addition, BioFire continues to broaden its FilmArray test menu, and is currently developing a blood culture ID panel, a gastrointestinal panel, and a meningitis panel.

BioFire holds more than 85 patents related to polymerase chain reaction (PCR), and it has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research, and military markets. BioFire customers include the Department of Health and Human Services, the Department of Defense, state and local law enforcement, clinical laboratories, and research institutions across a spectrum of fields and industries around the world.

Contact:

BioFire Diagnostics, Inc.  
Wade Stevenson  
Director of Marketing; Clinical Products  
801-736-6354 x463

BioFire Diagnostics, Inc.  
390 Wakara Way • Salt Lake City, Utah 84108, USA • 801 736 6354 local • 1 800 735 6544 toll-free • 801 588 0507 fax  
BioFireDX.com
FOR IMMEDIATE RELEASE
wade.stevenson@biofiredx.com

# # #